GlassScriptPhysician profile
John L May
NPI 1932151131
$1,653.87
in general payments reported to CMS, 2019-2025
25 companies · $34.73 in 2025
The $34.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $256 · 2023: $86.29 · 2024: $324 · 2025: $34.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $337.75 | 2019-2024 | Ozempic, Rybelsus |
| Organogenesis INC. | $227.68 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $156.17 | 2019-2020 | |
| Dexcom, INC. | $142.08 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $133.20 | 2019-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $94.16 | 2019-2024 | Jardiance |
| Pfizer INC. | $82.76 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $72.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.58 | 2019 | |
| Astellas Pharma US INC | $44.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $40.91 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.89 | 2024 | Jardiance |
| Eisai INC. | $28.18 | 2019 | |
| Amarin Pharma, INC. | $28.12 | 2019 | |
| Upsher-Smith Laboratories LLC | $26.85 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $20.04 | 2019 | |
| Exact Sciences Corporation | $19.08 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $18.61 | 2019 | |
| Abbott Laboratories | $15.32 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $14.90 | 2019 | |
| Merck Sharp & Dohme LLC | $14.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.20 | 2019 | |
| Allergan, INC. | $12.95 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.92 | 2019 | |
| Shire North American Group INC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.